Tyrosine kinase inhibitors are small molecules that bind to the receptor site of the kinase enzyme available at cell surface.
The “Tyrosine Kinase Inhibitors Industry Forecast” looks at past sales and reviews total world Tyrosine Kinase Inhibitors sales in 2022, providing a comprehensive analysis by region and market sector of projected Tyrosine Kinase Inhibitors sales for 2023 through 2029. With Tyrosine Kinase Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tyrosine Kinase Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Tyrosine Kinase Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tyrosine Kinase Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Tyrosine Kinase Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tyrosine Kinase Inhibitors and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tyrosine Kinase Inhibitors.
The global Tyrosine Kinase Inhibitors market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
The global tyrosine kinase inhibitors market is expanding owing to high prevalence and increase in incidence of cancer across the globe.
This report presents a comprehensive overview, market shares, and growth opportunities of Tyrosine Kinase Inhibitors market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
BCR-ABL Tyrosine Kinase Inhibitor
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
Segmentation by application
Chronic Myeloid Leukemia (CML)
Lung Cancer
Breast Cancer
Renal Cell Cancer
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Pfizer
Novartis
Bristol-Myers Squibb
Bayer
Boehringer Ingelheim International
F. Hoffmann-La Roche
Johnson & Johnson
Eisai
Key Questions Addressed in this Report
What is the 10-year outlook for the global Tyrosine Kinase Inhibitors market?
What factors are driving Tyrosine Kinase Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Tyrosine Kinase Inhibitors market opportunities vary by end market size?
How does Tyrosine Kinase Inhibitors break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Tyrosine Kinase Inhibitors Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Tyrosine Kinase Inhibitors by Country/Region, 2018, 2022 & 2029
2.2 Tyrosine Kinase Inhibitors Segment by Type
2.2.1 BCR-ABL Tyrosine Kinase Inhibitor
2.2.2 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
2.2.3 Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
2.3 Tyrosine Kinase Inhibitors Sales by Type
2.3.1 Global Tyrosine Kinase Inhibitors Sales Market Share by Type (2018-2023)
2.3.2 Global Tyrosine Kinase Inhibitors Revenue and Market Share by Type (2018-2023)
2.3.3 Global Tyrosine Kinase Inhibitors Sale Price by Type (2018-2023)
2.4 Tyrosine Kinase Inhibitors Segment by Application
2.4.1 Chronic Myeloid Leukemia (CML)
2.4.2 Lung Cancer
2.4.3 Breast Cancer
2.4.4 Renal Cell Cancer
2.4.5 Others
2.5 Tyrosine Kinase Inhibitors Sales by Application
2.5.1 Global Tyrosine Kinase Inhibitors Sale Market Share by Application (2018-2023)
2.5.2 Global Tyrosine Kinase Inhibitors Revenue and Market Share by Application (2018-2023)
2.5.3 Global Tyrosine Kinase Inhibitors Sale Price by Application (2018-2023)
3 Global Tyrosine Kinase Inhibitors by Company
3.1 Global Tyrosine Kinase Inhibitors Breakdown Data by Company
3.1.1 Global Tyrosine Kinase Inhibitors Annual Sales by Company (2018-2023)
3.1.2 Global Tyrosine Kinase Inhibitors Sales Market Share by Company (2018-2023)
3.2 Global Tyrosine Kinase Inhibitors Annual Revenue by Company (2018-2023)
3.2.1 Global Tyrosine Kinase Inhibitors Revenue by Company (2018-2023)
3.2.2 Global Tyrosine Kinase Inhibitors Revenue Market Share by Company (2018-2023)
3.3 Global Tyrosine Kinase Inhibitors Sale Price by Company
3.4 Key Manufacturers Tyrosine Kinase Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tyrosine Kinase Inhibitors Product Location Distribution
3.4.2 Players Tyrosine Kinase Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Tyrosine Kinase Inhibitors by Geographic Region
4.1 World Historic Tyrosine Kinase Inhibitors Market Size by Geographic Region (2018-2023)
4.1.1 Global Tyrosine Kinase Inhibitors Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Tyrosine Kinase Inhibitors Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Tyrosine Kinase Inhibitors Market Size by Country/Region (2018-2023)
4.2.1 Global Tyrosine Kinase Inhibitors Annual Sales by Country/Region (2018-2023)
4.2.2 Global Tyrosine Kinase Inhibitors Annual Revenue by Country/Region (2018-2023)
4.3 Americas Tyrosine Kinase Inhibitors Sales Growth
4.4 APAC Tyrosine Kinase Inhibitors Sales Growth
4.5 Europe Tyrosine Kinase Inhibitors Sales Growth
4.6 Middle East & Africa Tyrosine Kinase Inhibitors Sales Growth
5 Americas
5.1 Americas Tyrosine Kinase Inhibitors Sales by Country
5.1.1 Americas Tyrosine Kinase Inhibitors Sales by Country (2018-2023)
5.1.2 Americas Tyrosine Kinase Inhibitors Revenue by Country (2018-2023)
5.2 Americas Tyrosine Kinase Inhibitors Sales by Type
5.3 Americas Tyrosine Kinase Inhibitors Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tyrosine Kinase Inhibitors Sales by Region
6.1.1 APAC Tyrosine Kinase Inhibitors Sales by Region (2018-2023)
6.1.2 APAC Tyrosine Kinase Inhibitors Revenue by Region (2018-2023)
6.2 APAC Tyrosine Kinase Inhibitors Sales by Type
6.3 APAC Tyrosine Kinase Inhibitors Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Tyrosine Kinase Inhibitors by Country
7.1.1 Europe Tyrosine Kinase Inhibitors Sales by Country (2018-2023)
7.1.2 Europe Tyrosine Kinase Inhibitors Revenue by Country (2018-2023)
7.2 Europe Tyrosine Kinase Inhibitors Sales by Type
7.3 Europe Tyrosine Kinase Inhibitors Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tyrosine Kinase Inhibitors by Country
8.1.1 Middle East & Africa Tyrosine Kinase Inhibitors Sales by Country (2018-2023)
8.1.2 Middle East & Africa Tyrosine Kinase Inhibitors Revenue by Country (2018-2023)
8.2 Middle East & Africa Tyrosine Kinase Inhibitors Sales by Type
8.3 Middle East & Africa Tyrosine Kinase Inhibitors Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tyrosine Kinase Inhibitors
10.3 Manufacturing Process Analysis of Tyrosine Kinase Inhibitors
10.4 Industry Chain Structure of Tyrosine Kinase Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tyrosine Kinase Inhibitors Distributors
11.3 Tyrosine Kinase Inhibitors Customer
12 World Forecast Review for Tyrosine Kinase Inhibitors by Geographic Region
12.1 Global Tyrosine Kinase Inhibitors Market Size Forecast by Region
12.1.1 Global Tyrosine Kinase Inhibitors Forecast by Region (2024-2029)
12.1.2 Global Tyrosine Kinase Inhibitors Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Tyrosine Kinase Inhibitors Forecast by Type
12.7 Global Tyrosine Kinase Inhibitors Forecast by Application
13 Key Players Analysis
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.1.3 AstraZeneca Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.2.3 Pfizer Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.3.3 Novartis Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.5.3 Bayer Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Boehringer Ingelheim International
13.6.1 Boehringer Ingelheim International Company Information
13.6.2 Boehringer Ingelheim International Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.6.3 Boehringer Ingelheim International Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Boehringer Ingelheim International Main Business Overview
13.6.5 Boehringer Ingelheim International Latest Developments
13.7 F. Hoffmann-La Roche
13.7.1 F. Hoffmann-La Roche Company Information
13.7.2 F. Hoffmann-La Roche Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.7.3 F. Hoffmann-La Roche Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 F. Hoffmann-La Roche Main Business Overview
13.7.5 F. Hoffmann-La Roche Latest Developments
13.8 Johnson & Johnson
13.8.1 Johnson & Johnson Company Information
13.8.2 Johnson & Johnson Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.8.3 Johnson & Johnson Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Johnson & Johnson Main Business Overview
13.8.5 Johnson & Johnson Latest Developments
13.9 Eisai
13.9.1 Eisai Company Information
13.9.2 Eisai Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.9.3 Eisai Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Eisai Main Business Overview
13.9.5 Eisai Latest Developments
14 Research Findings and Conclusion
*If Applicable.